Navigation Links
Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
Date:5/31/2011

toxicities that are not related to underlying leukemia, clinically significant moderate or severe nonhematologic toxicities, laboratory abnormalities or concomitant use of strong CYP3A4 inhibitors.

Please see full Prescribing Information.

About the compounds BEZ235, TKI258 (dovitinib), LDE225 and LBH589 (panobinostat)Because these are investigational compounds, the safety and efficacy profile of BEZ235, TKI258 (dovitinib), LDE225 and LBH589 (panobinostat) have not yet been fully established. Access to these investigational compounds is available only through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the compound. Because of uncertainty of clinical trials, there is no guarantee that BEZ235, TKI258 (dovitinib), LDE225 and LBH589 (panobinostat) will ever be commercially available anywhere in the world.

About ZOMETAZOMETA (zoledronic acid) 4 mg/5 mL Injection is a treatment for hypercalcemia of malignancy (HCM; a condition resulting in high calcium blood levels due to cancer). ZOMETA is also used to reduce and delay bone complications due to multiple myeloma and bone metastases from solid tumors; used with anti-cancer medicines. ZOMETA is not an anti-cancer therapy. If you have prostate cancer, you should have failed treatment with at least one hormonal therapy prior to taking ZOMETA.

ZOMETA Important Safety InformationDo not use ZOMETA if you have had a severe allergic reaction to zoledronic acid or any components of ZOMETA. These reactions, including rare cases of hives and angioedema (swelling often near your eyes and lips), and very rare cases of life-threatening allergic reactions, have been reported. ZOMETA is in a class of drugs called bisphosphonates, and contains the same active ingredient as that found in Reclast® (zoledronic acid). If you are treated with ZOMETA, you should not be treated with Recl
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014 RoundTable ... focused exclusively on the healthcare industry, announced today ... The Lubrizol Corporation ("Lubrizol"). Lubrizol, a Berkshire Hathaway ... and supplies technologies to customers in the global ... transaction were not disclosed. Vesta is ...
(Date:8/1/2014)... Minn. , Aug. 1, 2014 ... medical technologies company, announced today that it has ... held manufacturer of cardiorespiratory diagnostic products based in ... MediSoft has served the European cardiorespiratory diagnostics market ... 2013 revenues of approximately €4.7 million ($6.3 million) ...
(Date:8/1/2014)... , Aug. 1, 2014 Dyadic International, Inc. ... and proprietary technologies are used to develop, manufacture and ... chemical, biopharmaceutical and industrial enzyme industries, announced today that ... quarter ended June 30, 2014 after market close on ... call that day at 5:00 p.m. Eastern Time to ...
Breaking Medicine Technology:RoundTable Healthcare Partners Announces Sale of Vesta Funding, Inc. to The Lubrizol Corporation 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3
(Date:8/1/2014)... plays a central role in regulating appetite and whole-body ... the brain,s control of food intake and body weight, ... has been unclear. A new study in ... PPARγ activity in a type of neuron known as ... to high-fat diet. Sabrina Diano and colleagues at ...
(Date:8/1/2014)... News) -- Almost 140 people die every year ... United States. But there are several simple ... injury prevention coordinator at Cincinnati Children,s Hospital Medical ... medical center news release. "As families begin ... important for parents and children to go over ...
(Date:8/1/2014)... Chicago, Illinois (PRWEB) August 01, 2014 ... filed across the country, Ronald E. Johnson, Jr. has ... injured by AndroGel and other testosterone medications. Since the ... & Johnson, P.S.C. have worked diligently to investigate and ... strokes, pulmonary embolisms, and blood clots as a result ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Market ... research reports have been added to its catalogue. ... Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing ... key pharma industry drivers include, among others, increasing ... personal hygiene. In 2015, the pharma market in ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, ... a time-honored destination for a good cut and conversation. ... be the spot to tackle an often overlooked health concern: ... partnership, the U.S. Centers for Disease Control and Prevention, together ... help of barbershop staff to both discuss and diagnose high ...
Breaking Medicine News(10 mins):Health News:Expert Offers School Bus Safety Tips 2Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 2Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 3
... who were separated by a rare surgical operation in Raipur ... said the next 24 to 48 hours are extremely critical. ... does not mean they are out of danger, we are ... the improvement so far," Ashok Sharma, head of the surgical ...
... have challenged the current theory on the causes and ... imbalance between two peptides may be responsible for preventing ... that two peptides, AB42 and AB40, must be in ... and assistant professor of biology at Rensselaer. ...
... only two certainties in life: "death and taxes." Joseph Dello ... need for wearing reading glasses after forty, a condition ... himself with a team of researches who in the past ... They are now hard at work with what may be ...
... the receptor in cells of the peripheral nervous system that ... ,The finding, reported on-line in the journal ... by which the body detects temperature sensation. But in so ... body experiences intense stimuli temperature, in this case ...
... Torisel (temsirolimus) for the treatment of a certain type of ... was approved based on a study that showed use of ... The drug is an enzyme inhibitor, a protein that regulates ... have made significant advances in the battle against kidney cancer,' ...
... is only a pretext for multinational corporations to take control ... in US charge. With sales of over $35 billion ... it takes to buy up pristine springs in some of ... Nestl, which controls one-third of the U.S. market and sells ...
Cached Medicine News:Health News:Specific Imbalance Between Two Peptides may Cause Alzheimer's 2Health News:Cure for Reading Glasses? 2Health News:Detecting Cold, Feeling Pain: Study Reveals Why Menthol Fresh 2Health News:Detecting Cold, Feeling Pain: Study Reveals Why Menthol Fresh 3Health News:FDA: New Drug for Advance Kidney Cancer 2Health News:Multinationals Exploit Groundwater Sources, and People Suffer 2Health News:Multinationals Exploit Groundwater Sources, and People Suffer 3Health News:Multinationals Exploit Groundwater Sources, and People Suffer 4Health News:Multinationals Exploit Groundwater Sources, and People Suffer 5
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
Multi-Tier Shaker...
... The Thermo Labsystems Wellmix is a ... and time settings. The shaking speed is ... shaking frequency, high speed and a small ... assays. The shaking time is quick and ...
Medicine Products: